Short-term mortality in alcohol-related hepatitis (AH) is high, and no current therapy results in durable benefit. A role for interleukin (IL)-1β has been demonstrated in the pathogenesis of alcohol-induced steatohepatitis. This study explored the safety and efficacy of canakinumab (CAN), a monoclonal antibody targeting IL-1β, in the treatment of patients with AH.

中文翻译：

---

酒精相关性肝炎中的 IL-1 信号抑制：卡那奴单抗的随机、双盲、安慰剂对照试验


酒精相关性肝炎 (AH) 的短期死亡率很高，并且目前的治疗方法无法带来持久的益处。白介素 (IL)-1β 在酒精性脂肪性肝炎的发病机制中发挥着重要作用。本研究探讨了卡那奴单抗 (CAN)（一种靶向 IL-1β 的单克隆抗体）治疗 AH 患者的安全性和有效性。